Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

November 2023

Global, Regional, and National Burden of Other Musculoskeletal Disorders, 1990–2020, and Projections to 2050: A Systematic Analysis of the Global Burden of Disease Study 2021

Lancet Rheumatol 2023;5:e670–82 doi 10.1016/S2665-9913(23)00232-1

GBD 2021 Other Musculoskeletal Disorders Collaborators

As part of the GBD 2021, the authors provide updated estimates for the global burden of musculoskeletal disorders, excluding RA, osteoarthritis, low back pain, neck pain, and gout. In 2020, the total years lived with disability globally was estimated to be 42.7 million, which was a 122% increase from 1990. Over the same time period, mortality increased by 199%. The study forecasts an increase in cases by 2050 in all regions, with the exception of Central Europe.

Keywords:

Bimekizumab Treatment in Patients With Active Axial Spondyloarthritis: 52-week Efficacy and Safety from the Randomised Parallel Phase 3 BE MOBILE 1 and BE MOBILE 2 Studies

Ann Rheum Dis. 2023;83(2):199–213 doi 10.1136/ard-2023-224803

Xu H,

Vaux T,

Baraliakos, et al. present data from two Phase 3 studies, BE MOBILE 1 and BE MOBILE 2, that investigated the clinical efficacy and safety of bimekizumab in axSpA patients. They found that bimekizumab had sustained and consistent efficacy in patients with nr-axSpA and r-axSpA.

Keywords:

October 2023

Efficacy and Safety of Upadacitinib in Patients with Ankylosing Spondylitis Refractory to Biologic Therapy: 1-year Results From the Open-label Extension of a Phase III Study

Arthritis Res Ther 2023; 2023;18;25(1):172 doi 10.1186/s13075-023-03128-1

Inman R,

Li Y,

Bu X,

Shmagel A,

Wung P,

Song I,

Deodhar A

The efficacy and safety of updacitinib in bDMARD-IR patients with AS were sustained through to one year in an open-label extension of the SELECT-AXIS 2 study.

Keywords:

July 2023

Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis

Rheumatol Ther 2023; 10:679–91 doi 10.1007/s40744-023-00536-2

Song IH,

Ganz F,

Stigler J,

Deodhar A

Upadacitinib significantly improved patient-reported outcomes in AxSpA patients with bDMARD-IR after 14 Weeks of treatment. There were notable improvements in disease activity, pain, fatigue, function, HRQoL, and work productivity.

Keywords:

June 2022

Effect of Tofacitinib on Pain, Fatigue, Health-related Quality of Life and Work Productivity in Patients with Active Ankylosing Spondylitis: Results from A Phase III, Randomised, Double-blind, Placebo-controlled Trial

RMD Open 2022 doi:10.1136/rmdopen-2022-002253

Wang L,

Wang C,

Wu J,

Dina O,

Fallon L,

Strand V

Navarro-Compán et al, determined the effectiveness of tofacitinib in patients with active ankylosing spondylitis in a Phase III, randomised, double-blind, placebo-controlled trial.